Literature DB >> 18546366

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations.

Eva Pros1, Carolina Gómez, Thamar Martín, Pere Fábregas, Eduard Serra, Conxi Lázaro.   

Abstract

Neurofibromatosis type 1 (NF1) is a common autosomal dominant genetic disorder caused by mutations in the NF1 gene. In this paper we report our experience using the cDNA-SSCP/HD analysis as a mutational screening approach and the double characterization of all mutations at the DNA and RNA levels. Two hundred and eighty-two different mutations (in 374 independent patients) were identified, 140 of which were novel in our population. Most of these mutations are unique and distributed along the gene. However, we also detected 37 recurrent mutations. Our approach is limited with respect to the detection of single base substitutions, but it is highly effective in the detection of frameshift mutations and mutations that affect the correct splicing. Due to this bias we focus here in the characterization of these two types of mutations. Forty-seven percent of mutations found were frameshift mutations, with small deletions being 2.3 times more common than small insertions. At the mRNA level, 44% of mutations affected the correct splicing, 80% of them located in the consensus sequences, with the donor site being much more frequently involved. The remaining 20% consisted of mutations located in deep intronic sites and mutations located in the coding region. In general the latter group produces different types of mutated transcripts with specific proportions for each mutation. The double characterization of mutations at the DNA and RNA levels enables to detect a broader spectrum of mutations than any single level approach, and provides a greater understanding of their molecular pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18546366     DOI: 10.1002/humu.20826

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  41 in total

Review 1.  The NF1 somatic mutational landscape in sporadic human cancers.

Authors:  Charlotte Philpott; Hannah Tovell; Ian M Frayling; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2017-06-21       Impact factor: 4.639

2.  Intronic splicing mutations in PTCH1 cause Gorlin syndrome.

Authors:  Zaynab Bholah; Miriam J Smith; Helen J Byers; Emma K Miles; D Gareth Evans; William G Newman
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

3.  NF1 single and multi-exons copy number variations in neurofibromatosis type 1.

Authors:  Apolline Imbard; Eric Pasmant; Audrey Sabbagh; Armelle Luscan; Magali Soares; Philippe Goussard; Hélène Blanché; Ingrid Laurendeau; Salah Ferkal; Michel Vidaud; Stéphane Pinson; Christine Bellanne-Chantelot; Dominique Vidaud; Pierre Wolkenstein; Béatrice Parfait
Journal:  J Hum Genet       Date:  2015-01-29       Impact factor: 3.172

4.  Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation types.

Authors:  Eungu Kang; Yoon-Myung Kim; Go Hun Seo; Arum Oh; Hee Mang Yoon; Young-Shin Ra; Eun Key Kim; Heyry Kim; Sun-Hee Heo; Gu-Hwan Kim; Mark J Osborn; Jakub Tolar; Han-Wook Yoo; Beom Hee Lee
Journal:  J Hum Genet       Date:  2019-11-28       Impact factor: 3.172

5.  Clinical and molecular characteristics of thirty NF1 variants in Chinese patients with neurofibromatosis type 1.

Authors:  Wen Wang; Weibing Qin; Hongsong Ge; Xiangsheng Kong; Chao Xie; Yunge Tang; Ming Li
Journal:  Mol Biol Rep       Date:  2019-06-14       Impact factor: 2.316

6.  A highly sensitive genetic protocol to detect NF1 mutations.

Authors:  María Carmen Valero; Yolanda Martín; Elisabete Hernández-Imaz; Alba Marina Hernández; Germán Meleán; Ana María Valero; Francisco Javier Rodríguez-Álvarez; Dolores Tellería; Concepción Hernández-Chico
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

7.  PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.

Authors:  Maria Currás-Freixes; Elena Piñeiro-Yañez; Cristina Montero-Conde; María Apellániz-Ruiz; Bruna Calsina; Veronika Mancikova; Laura Remacha; Susan Richter; Tonino Ercolino; Natalie Rogowski-Lehmann; Timo Deutschbein; María Calatayud; Sonsoles Guadalix; Cristina Álvarez-Escolá; Cristina Lamas; Javier Aller; Julia Sastre-Marcos; Conxi Lázaro; Juan C Galofré; Ana Patiño-García; Amparo Meoro-Avilés; Judith Balmaña-Gelpi; Paz De Miguel-Novoa; Milagros Balbín; Xavier Matías-Guiu; Rocío Letón; Lucía Inglada-Pérez; Rafael Torres-Pérez; Juan M Roldán-Romero; Cristina Rodríguez-Antona; Stephanie M J Fliedner; Giuseppe Opocher; Karel Pacak; Esther Korpershoek; Ronald R de Krijger; Laurent Vroonen; Massimo Mannelli; Martin Fassnacht; Felix Beuschlein; Graeme Eisenhofer; Alberto Cascón; Fátima Al-Shahrour; Mercedes Robledo
Journal:  J Mol Diagn       Date:  2017-05-25       Impact factor: 5.568

8.  Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment.

Authors:  Eva Pros; Juana Fernández-Rodríguez; Llúcia Benito; Anna Ravella; Gabriel Capellá; Ignacio Blanco; Eduard Serra; Conxi Lázaro
Journal:  Eur J Hum Genet       Date:  2009-11-25       Impact factor: 4.246

9.  A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

Authors:  Steven R Whittaker; Jean-Philippe Theurillat; Eliezer Van Allen; Nikhil Wagle; Jessica Hsiao; Glenn S Cowley; Dirk Schadendorf; David E Root; Levi A Garraway
Journal:  Cancer Discov       Date:  2013-01-03       Impact factor: 39.397

10.  Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis.

Authors:  Lauren T McGillicuddy; Jody A Fromm; Pablo E Hollstein; Sara Kubek; Rameen Beroukhim; Thomas De Raedt; Bryan W Johnson; Sybil M G Williams; Phioanh Nghiemphu; Linda M Liau; Tim F Cloughesy; Paul S Mischel; Annabel Parret; Jeanette Seiler; Gerd Moldenhauer; Klaus Scheffzek; Anat O Stemmer-Rachamimov; Charles L Sawyers; Cameron Brennan; Ludwine Messiaen; Ingo K Mellinghoff; Karen Cichowski
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.